Kairos Pharma, Ltd.
KAPA
$0.34
-$0.02-5.28%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.01M | 877.00K | 827.00K | 960.00K | 773.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.69M | 1.42M | 1.44M | 1.46M | 1.27M |
| Operating Income | -1.69M | -1.42M | -1.44M | -1.46M | -1.27M |
| Income Before Tax | -1.65M | -1.37M | -1.40M | -1.42M | -1.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.65M | -1.37M | -1.40M | -1.42M | -1.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.65M | -1.37M | -1.40M | -1.42M | -1.26M |
| EBIT | -1.69M | -1.42M | -1.44M | -1.46M | -1.27M |
| EBITDA | -1.65M | -1.38M | -1.40M | -1.42M | -1.23M |
| EPS Basic | -0.08 | -0.07 | -0.07 | -0.08 | -0.08 |
| Normalized Basic EPS | -0.05 | -0.04 | -0.04 | -0.05 | -0.05 |
| EPS Diluted | -0.08 | -0.07 | -0.07 | -0.08 | -0.08 |
| Normalized Diluted EPS | -0.05 | -0.04 | -0.04 | -0.05 | -0.05 |
| Average Basic Shares Outstanding | 21.01M | 20.85M | 20.21M | 17.21M | 15.88M |
| Average Diluted Shares Outstanding | 21.01M | 20.85M | 20.21M | 17.21M | 15.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |